Clinical Trial Update: A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on a C13-CAC breath test for patients with PPI-resistant gastroesophageal reflux disease (GERD) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• C13-CAC breath test (C13-CAC breath test)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Gastroesophageal Reflux Disease | Phase 2 | Status: COMPLETED